NCR2 (natural cytotoxicity triggering receptor 2)

Horton, Nathan; Bowen, Kelly; Mathew, Porunelloor A.

doi:10.4267/2042/52072

Cited by 1 publication

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Culture medium was prepared as following; DMEM (Gibco, 41965-039) supplemented with 10% fetal calf serum (FCS) (Gibco, 12657-029), 1% l -glutamine (BI, 03-020-1A), 1% Pen–Strep (BI, 03-031-1B), 1% sodium pyruvate (BI, 03-042-1B), 1% MEM-Eagle (BI, 01-340-1B), and 1% HEPES 1 M (BI, 03-025-1B). NK92-44-1 cells were cultured as previously described ( 11 , 12 ).…”

Section: Methodsmentioning

confidence: 99%

“…IFNγ secretion assay and ELISA assay were done as previously described ( 11 , 12 ). NKp44-pep8, pep9, and pep10 (10 or 20 µg) were added to the IFNγ secretion assay.…”

Section: Methodsmentioning

confidence: 99%

“…NKp44 recognizes proliferating cell nuclear antigen (PCNA) expressed on the membrane of cancer cells ( 4 – 10 ). PCNA recognized by NKp44 can lead to inhibition of NK cell functions ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death

et al. 2018

View full text Add to dashboard Cite

Proliferating cell nuclear antigen (PCNA) is considered as a hub protein and is a key regulator of DNA replication, repair, cell cycle control, and apoptosis. PCNA is overexpressed in many cancer types, and PCNA overexpression is correlated with cancer virulence. Membrane-associated PCNA is a ligand for the NKp44 (NCR2) innate immune receptor. The purpose of this study was to characterize the PCNA-binding site within NKp44. We have identified NKp44-derived linear peptide (pep8), which can specifically interact with PCNA and partly block the NKp44–PCNA interaction. We then tested whether NKp44-derived pep8 (NKp44-pep8) fused to cell-penetrating peptides (CPPs) can be employed for targeting the intracellular PCNA for the purpose of anticancer therapy. Treatment of tumor cells with NKp44-pep8, fused to R11-NLS cell-penetrating peptide (R11-NLS-pep8), reduced cell viability and promoted cell death, in various murine and human cancer cell lines. Administration of R11-NLS-pep8 to tumor-bearing mice suppressed tumor growth in the 4T1 breast cancer and the B16 melanoma in vivo models. We therefore identified the NKp44 binding site to PCNA and further developed an NKp44-peptide-based agent that can inhibit tumor growth through interfering with the function of intracellular PCNA in the tumor cell.

show abstract

Section: Methodsmentioning

confidence: 99%

“…IFNγ secretion assay and ELISA assay were done as previously described ( 11 , 12 ). NKp44-pep8, pep9, and pep10 (10 or 20 µg) were added to the IFNγ secretion assay.…”

Section: Methodsmentioning

confidence: 99%